Gordon Cook

22.5k total citations · 3 hit papers
383 papers, 11.2k citations indexed

About

Gordon Cook is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Gordon Cook has authored 383 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 218 papers in Hematology, 137 papers in Oncology and 114 papers in Molecular Biology. Recurrent topics in Gordon Cook's work include Multiple Myeloma Research and Treatments (179 papers), Protein Degradation and Inhibitors (76 papers) and Cancer Treatment and Pharmacology (59 papers). Gordon Cook is often cited by papers focused on Multiple Myeloma Research and Treatments (179 papers), Protein Degradation and Inhibitors (76 papers) and Cancer Treatment and Pharmacology (59 papers). Gordon Cook collaborates with scholars based in United Kingdom, United States and Germany. Gordon Cook's co-authors include Gareth J. Morgan, Faith E. Davies, Graham Jackson, Roger G. Owen, Mark T. Drayson, Sylvia Feyler, Rachel S. Mulligan, S. Sherlock, Walter M. Gregory and Sue Bell and has published in prestigious journals such as Nature, The Lancet and The Journal of Experimental Medicine.

In The Last Decade

Gordon Cook

358 papers receiving 10.6k citations

Hit Papers

Multiple myeloma: EHA-ESM... 1971 2026 1989 2007 2021 1971 2020 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
    2021 460 citations Gordon Cook, Fredrik Schjesvold et al. profile →
  2. Controlled Prospective Trial of Corticosteroid Therapy in Active Chronic Hepatitis
    1971 403 citations Gordon Cook et al. profile →
  3. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
    2020 330 citations Gordon Cook et al. Blood profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Gordon Cook 5.8k 4.3k 3.4k 1.6k 1.2k 383 11.2k
Janice Gabrilove 4.6k 0.8× 3.3k 0.8× 4.3k 1.2× 2.0k 1.3× 1.2k 1.0× 148 11.0k
Ann A. Jakubowski 3.9k 0.7× 3.1k 0.7× 2.2k 0.6× 1.6k 1.0× 713 0.6× 233 9.3k
James F. Holland 3.4k 0.6× 5.6k 1.3× 4.3k 1.3× 1.3k 0.8× 1.4k 1.2× 400 15.6k
Orhan Sezer 3.9k 0.7× 5.2k 1.2× 4.6k 1.4× 424 0.3× 1.1k 0.9× 171 11.0k
Jerome B. Zeldis 10.1k 1.7× 5.5k 1.3× 7.8k 2.3× 894 0.6× 3.4k 2.8× 202 15.4k
Tapani Ruutu 6.8k 1.2× 2.1k 0.5× 1.4k 0.4× 1.5k 0.9× 2.3k 2.0× 221 10.2k
Magnus Björkholm 5.6k 1.0× 4.0k 0.9× 5.0k 1.5× 2.5k 1.5× 4.7k 4.0× 488 16.3k
Ernst Holler 9.3k 1.6× 3.1k 0.7× 3.1k 0.9× 6.6k 4.1× 1.8k 1.5× 370 16.6k
Jacob M. Rowe 7.9k 1.4× 3.0k 0.7× 3.0k 0.9× 1.3k 0.8× 1.9k 1.6× 317 12.9k
Nicolaus Kröger 12.0k 2.1× 5.1k 1.2× 3.5k 1.0× 3.4k 2.1× 3.9k 3.3× 583 17.0k

Countries citing papers authored by Gordon Cook

Since Specialization
Citations

This map shows the geographic impact of Gordon Cook's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon Cook with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon Cook more than expected).

Fields of papers citing papers by Gordon Cook

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon Cook. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon Cook. The network helps show where Gordon Cook may publish in the future.

Co-authorship network of co-authors of Gordon Cook

This figure shows the co-authorship network connecting the top 25 collaborators of Gordon Cook. A scholar is included among the top collaborators of Gordon Cook based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon Cook. Gordon Cook is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Moore, Sally, Christopher Parrish, Laura Miller, et al.. (2025). Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group. British Journal of Haematology. 207(5). 1789–1801.
3.
Cairns, David A., Charlotte Pawlyn, Eugene B. Ferris, et al.. (2025). Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling. Blood. 146(22). 2670–2680.
4.
Petrie, Dennis, Anthony Harris, Laura Fanning, et al.. (2024). Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry. PLoS ONE. 19(8). e0308812–e0308812.
5.
6.
Kaiser, Martin, Andrew Hall, Katrina Walker, et al.. (2023). Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. Journal of Clinical Oncology. 41(23). 3945–3955. 54 indexed citations
7.
McIlroy, Graham, Sylvia Feyler, Rakesh Popat, et al.. (2023). Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic. Blood Cancer Journal. 13(1). 38–38. 8 indexed citations
8.
9.
Ramasamy, Karthik, Ross Sadler, Alison Turner, et al.. (2022). Immune response to COVID ‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response. British Journal of Haematology. 197(3). 293–301. 14 indexed citations
10.
Cairns, David A., Amy Holroyd, Charlotte Pawlyn, et al.. (2022). Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial. Blood. 141(14). 1666–1674. 21 indexed citations
11.
Jenner, Matthew, Charlotte Pawlyn, Faith E. Davies, et al.. (2022). The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. British Journal of Haematology. 201(2). 267–279. 11 indexed citations
12.
Tute, Ruth M. de, Charlotte Pawlyn, David A. Cairns, et al.. (2022). Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of Clinical Oncology. 40(25). 2889–2900. 40 indexed citations
13.
Migneco, G, Gina B. Scott, Jenny Down, et al.. (2021). Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche. Journal for ImmunoTherapy of Cancer. 9(3). e001803–e001803. 14 indexed citations
14.
Lamb, Maxine, Alexandra Smith, Daniel Painter, et al.. (2021). Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort. BMJ Open. 11(2). e041296–e041296. 6 indexed citations
15.
Corre, Jill, Michèle Sabbah, Fredrik Schjesvold, et al.. (2021). Recent Advancements in Hematology: Knowledge, Methods and Dissemination, Part 2. Repository@Hull (Worktribe) (University of Hull). 2(1). 79–88. 1 indexed citations
16.
Sherborne, Amy L., Vallari Shah, Sidra Ellis, et al.. (2017). Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. Blood. 130. 1767–1767. 2 indexed citations
17.
Pawlyn, Charlotte, Martin Kaiser, David A. Cairns, et al.. (2017). Factors Predicting Poor Outcomes for Myeloma Patients at Different Ages: Results from 3894 Patients in the Myeloma XI Trial. Blood. 130. 3040–3040. 2 indexed citations
18.
Cook, Gordon. (1996). Mary Darwin's illness. Notes and Records the Royal Society Journal of the History of Science. 50(1). 59–63. 2 indexed citations
19.
Cook, Gordon. (1973). Increased glycine absorption rate associated with acute bacterial infections in man. British Journal Of Nutrition. 29(3). 377–386. 12 indexed citations
20.
Cook, Gordon & M. S. R. Hutt. (1967). The Liver after Kwashiorkor. BMJ. 3(5563). 454–457. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Janice Gabrilove Breakdown of academic impact, for papers by Ann A. Jakubowski Breakdown of academic impact, for papers by James F. Holland Breakdown of academic impact, for papers by Orhan Sezer Breakdown of academic impact, for papers by Jerome B. Zeldis Breakdown of academic impact, for papers by Tapani Ruutu Breakdown of academic impact, for papers by Magnus Björkholm Breakdown of academic impact, for papers by Ernst Holler Breakdown of academic impact, for papers by Jacob M. Rowe Breakdown of academic impact, for papers by Nicolaus Kröger
Rankless by CCL
2026